The estimated Net Worth of Nicholas Galakatos is at least $4.6 Million dollars as of 28 September 2018. Nicholas Galakatos owns over 453,395 units of Cortexyme Inc stock worth over $3,165,640 and over the last 20 years Nicholas sold CRTX stock worth over $1,429,615.
Nicholas has made over 7 trades of the Cortexyme Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Nicholas bought 453,395 units of CRTX stock worth $6,800,925 on 28 September 2018.
The largest trade Nicholas's ever made was buying 547,446 units of Cortexyme Inc stock on 20 June 2005 worth over $3,000,004. On average, Nicholas trades about 62,879 units every 180 days since 2004. As of 28 September 2018 Nicholas still owns at least 1,623,405 units of Cortexyme Inc stock.
You can see the complete history of Nicholas Galakatos stock trades at the bottom of the page.
Nicholas's mailing address filed with the SEC is C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR, BOSTON, MA, 02199.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: